How Canopy Growth Makes its Money: Revenue Breakdown

How Does Canopy Growth Make its Money?

Canopy Growth is one of the most widely followed cannabis companies in the world, having been the first North American cannabis company to list on the New York Stock Exchange. The company operates in the Canadian adult-use and medical cannabis markets, and has been restructuring aggressively to survive after burning through billions in cash since legalization. Canopy made headlines with a $4 billion investment from Constellation Brands (maker of Corona beer) in 2018 — the largest corporate bet on cannabis ever — though the investment has lost significant value. The company has pivoted its US strategy through a complex arrangement with Canopy USA, which holds options on US cannabis companies (Acreage Holdings, Wana Brands, Jetty Extracts) that would be exercised if US federal legalization occurs.

Canopy Growth (CGC) Business Model

Canopy Growth Competitors

Canopy Growth’s key competitors and comparable public companies in the cannabis sector include Tilray Brands, Constellation Brands, Pfizer, and Anheuser Busch Inbev. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Canopy Growth stacks up by comparing their revenue breakdown, margins, and growth metrics.

Revenue Breakdown

Canada Cannabis (Adult-Use & Medical) — 71% of Revenue

Revenue from the sale of dried flower, pre-rolls, oils, edibles, beverages (including THC-infused drinks through partnerships), and other cannabis products in the Canadian legal market. Revenue declined 7.4% to $250 million in 2024, reflecting the brutal competitive dynamics of the Canadian cannabis market — widespread oversupply, intense price compression, illicit market competition, and a fragmented provincial distribution system. Canada legalized adult-use cannabis in October 2018, and the initial excitement attracted massive capital investment that built far more production capacity than the market could absorb.

Canopy Growth operates several brands including Tweed (the core mass-market brand), Doja (premium craft), 7ACRES (premium flower), and Deep Space (beverages). The medical cannabis component serves registered patients through the Spectrum Therapeutics brand. Despite being one of the earliest and most capitalized Canadian licensed producers, Canopy has consistently lost market share to lower-cost operators like Tilray, HEXO, and private companies that didn’t carry Canopy’s massive overhead burden.

International (Medical Cannabis, Germany) — 11% of Revenue

Revenue from medical cannabis sales in international markets, primarily Germany, which has one of the largest and fastest-growing legal medical cannabis markets in the world. Revenue grew 14.3% to $40 million in 2024. Germany partially legalized recreational cannabis in 2024, potentially expanding the addressable market significantly. Canopy has positioned itself in the German market through its Spectrum Therapeutics brand, supplying pharmacies with pharmaceutical-grade cannabis products. The international segment is Canopy’s brightest growth area, as European medical cannabis markets are expanding regulatory access.

Storz & Bickel (Vaporizers) — 17% of Revenue

Revenue from the sale of Storz & Bickel brand vaporizer devices, primarily the Mighty+ (portable) and Volcano (tabletop) — considered premium, best-in-class vaporizers globally. Revenue grew 9.1% to $60 million in 2024. Storz & Bickel, acquired by Canopy in 2019, is arguably the company’s most valuable asset per dollar of revenue — it operates independently of the cannabis regulatory environment, sells globally (including the US), has strong brand loyalty, and earns hardware-like margins that are far superior to the commodity cannabis business.

This Works (Wellness) — 4% of Revenue

Revenue from This Works brand natural skincare, sleep, and wellness products sold through retail and direct-to-consumer channels. Revenue was flat at $15 million in 2024. This is a non-core CBD/wellness brand that Canopy has considered divesting as part of its restructuring.

Canopy Growth (CGC) Income Statement

All values in millions USD unless otherwise stated.

Financial data sourced from Canopy Growth SEC Filings.

Canopy Growth (CGC) Key Financial Metrics

• Gross Margin: 20.0%
• Operating Margin: -51.4%
• Revenue Growth: -7.9%

Is Canopy Growth Profitable?

No, Canopy Growth is not profitable and has never generated an annual profit. The company reported a net loss of $300 million on just $350 million in revenue. The -51.4% operating margin reflects a corporate cost structure that remains massively oversized for the revenue base — a legacy of the 2018-2019 era when Canopy spent $4+ billion building out production facilities, acquiring companies (Acreage, Storz & Bickel, This Works, BioSteel), and funding ambitious expansion plans that assumed Canadian cannabis would become a much larger market much faster than it did. Operating expenses did decline meaningfully (from $350M to $250M) as Canopy cut headcount, closed facilities, and divested non-core assets (BioSteel was sold in 2024). The gross margin of 20.0% is thin for cannabis and reflects the commodity pricing environment. Canopy’s survival depends on continued cost cutting, cash preservation, and eventually US federal legalization triggering the Canopy USA structure.

Canopy Growth (CGC): What to Watch

1. US federal legalization or rescheduling — This is the existential catalyst. Canopy USA holds options on Acreage Holdings (multi-state US operator), Wana Brands (edibles), and Jetty Extracts that would be exercised if cannabis is rescheduled or legalized federally. The timing and form of US policy change determines whether these options have any value.
2. Cash runway and dilution risk — Canopy has burned billions in cumulative cash. The remaining cash position and the pace of cash burn determine whether the company can survive long enough for its US strategy to play out, or whether it needs additional dilutive equity raises.
3. German recreational legalization impact — Germany’s 2024 partial legalization of recreational cannabis could significantly expand Canopy’s addressable market in its strongest international territory.
4. Constellation Brands relationship — Constellation Brands owns approximately 35% of Canopy on a converted basis and has written down its investment by over $3 billion. Whether Constellation continues to support Canopy or seeks to exit impacts the company’s financial stability.
5. Restructuring progress — The path to positive free cash flow requires further cost cuts, facility closures, and potentially additional asset sales. Each quarter’s cash burn rate is the most important near-term metric.

Canopy Growth (CGC) Financial Summary

Canopy Growth is one of the most recognized cannabis companies globally, operating Canada Cannabis (71%, -7.4%), International medical (11%, +14.3%), Storz & Bickel vaporizers (17%, +9.1%), and This Works wellness (4%). Revenue declined 7.9% to $350 million in 2024 with a net loss of $300 million — significantly narrowed from $600 million the prior year through aggressive restructuring. The 20.0% gross margin and -51.4% operating margin reflect the commodity pricing environment in Canadian cannabis and an oversized cost structure being rightsized. The investment thesis is binary: Canopy’s Canopy USA structure holds options on US cannabis assets that would become valuable upon federal legalization, but the company must survive financially until that catalyst materializes.